New strategy for COVID-19 vaccination: targeting the receptor-binding domain of the SARS-CoV-2 spike protein

Monoclonal antibody designed for SARS-nCoV-2 spike protein of receptor binding domain on antigenic targeted epitopes for inhibition to prevent viral entry

Generation and utility of a single-chain fragment variable monoclonal antibody platform against a baculovirus expressed recombinant receptor binding domain of SARS-CoV-2 spike protein - ScienceDirect

Junzhi Wang's research works National Institutes for Food and Drug Control, China, Beijing (NIFDC) and other places

New strategy for COVID-19 vaccination: targeting the receptor-binding domain of the SARS-CoV-2 spike protein

COVID-19: Coronavirus replication, pathogenesis, and therapeutic strategies

AbCellera Biologics Inc. - New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials

Frontiers Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past

PDF) Modern Paradigm Towards Potential Target Identification for Antiviral (SARS-nCoV-2) and Anticancer Lipopeptides: A Pharmacophore-Based Approach

News & Comment Cellular & Molecular Immunology

Targeting ACE2 as a treatment for COVID

SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies

Structural biology of SARS-CoV-2 and implications for therapeutic development

Generation and utility of a single-chain fragment variable monoclonal antibody platform against a baculovirus expressed recombinant receptor binding domain of SARS-CoV-2 spike protein - ScienceDirect

News & Comment Cellular & Molecular Immunology

Targeting SARS-CoV-2 receptor binding domain, as adapted from a source